Physician profile
Arthur Geller
NPI 1629073127
$3,954.00
in general payments reported to CMS, 2019-2025
22 companies · $926 in 2025
The $926 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $127 · 2021: $342 · 2022: $477 · 2023: $798 · 2024: $1,050 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $408 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.82 |
| Education | $408.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.40 | 2019-2025 | |
| Janssen Biotech, INC. | $946.29 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $337.38 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.99 | 2019-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $213.72 | 2023 | |
| Pfizer INC. | $189.48 | 2023-2025 | |
| Ethicon US, LLC | $121.84 | 2021 | |
| Qol Medical, LLC | $120.75 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $100.73 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $100.11 | 2023-2024 | |
| Madrigal Pharmaceuticals | $87.40 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $69.43 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $62.53 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $61.84 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $58.13 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $38.89 | 2019-2022 | |
| Celgene Corporation | $33.18 | 2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $30.76 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2025 | Dupixent |
| Boston Scientific Corporation | $17.60 | 2023 | |
| Merck Sharp & Dohme LLC | $11.99 | 2019 | |
| Alfasigma USA, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.